Global Health logo

Global Health

MEDANTA NSE

Key Fundamentals

MidcapHospitalsHealthcare Services
Market Cap
₹38,784 Cr
Volatility
Moderate
P/E Ratio
69.95
EBITDA
₹1,018 Cr
Return on Equity
13.91%
Debt to Equity
0.3
Book Value
₹147.34
EPS
₹17.97
52W High
₹1,544
52W Low
₹956

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has delivered good profit growth of 80.7% CAGR over last 5 years

Weaknesses

1
  • Stock is trading at 9.82 times its book value

Growth Rate

Revenue Growth
19.56% higher than 3Y
Net Income Growth
15.13% lower than 3Y
Cash Flow Change
14.53% lower than 3Y
ROE
-2.11% lower than 3Y
ROCE
-12.4% higher than 3Y
EBITDA Margin (Avg.)
-10.97% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Global Health Ltd (Medanta) operates in the healthcare services sector with a market cap of ₹38,784 Cr and trades at a P/E of 71.1x. The company has delivered strong 5-year profit CAGR of ~81% and TTM sales growth of 21%, but valuations remain elevated at 9.91x book value with a negligible dividend yield of 0.03%.

Bull Case 7
  • Exceptional 5-year compounded profit growth of 81% CAGR demonstrates strong earnings scalability and operating leverage
  • TTM revenue growth of 21% indicates continued top-line momentum well above the 10-year sales CAGR of 12%
  • 3-year compounded sales growth of 18% reflects consistent demand for healthcare services across cycles
  • 3-year ROE averaging 16% indicates reasonably efficient capital deployment for a hospital business in expansion mode
  • 3-year stock CAGR of 29% suggests sustained market confidence in the company's growth trajectory
  • Market cap of ₹38,784 Cr positions Medanta as a large-cap healthcare platform with institutional investor appeal and liquidity
  • 10-year compounded sales growth of 12% shows a long track record of revenue expansion through multiple economic cycles
Bear Case 8
  • P/E ratio of 71.1x is significantly elevated, pricing in years of future growth and leaving little margin of safety
  • Price-to-book of 9.91x is very high, meaning investors pay nearly 10 times the net asset value per share
  • TTM compounded profit growth has decelerated sharply to 0%, signaling potential earnings stagnation after years of rapid growth
  • Dividend yield of just 0.03% offers virtually no income return, making the stock entirely dependent on capital appreciation
  • Last year ROE of 15% has dipped from the 3-year and 5-year average of 16%, suggesting slight moderation in return efficiency
  • The 10-year compounded profit growth of 13% is far below the 5-year figure of 81%, indicating that much of the profit surge is recent and may not be sustainable at the same pace
  • Healthcare services sector faces regulatory risks around pricing caps and government policy changes that could compress hospital margins
  • At 71.1x earnings, any miss on quarterly growth expectations could trigger sharp de-rating given the premium valuation

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Positives 2
  • ₹0.50 dividend proposed for FY26 Aug 21

    Global Health proposed a ₹0.50 per share dividend for FY25-26, to be approved at the 22nd AGM scheduled for September 16, 2026.

  • Strong institutional investor interest Sep 3

    Global Health has lined up meetings with marquee global investors including Polar Capital, Chikara Investments, Matthews International Capital, and Baillie Gifford through September 2026, signaling robust institutional engagement.

Neutral 4
  • Multiple analyst meets in September Sep 11

    Global Health scheduled back-to-back analyst and investor meetings on Sep 14, 17, and 18, organized by Jefferies and others, with no unpublished price-sensitive information to be shared.

  • AGM set for September 16 Aug 22

    The 22nd AGM will be held via VC/OAVM on Sep 16, 2026, covering adoption of FY26 financials, ₹0.50 dividend declaration, and re-election of director Pankaj Sahni.

  • Ongoing one-on-one investor engagements Aug 31

    The company held or scheduled one-to-one meetings with Matthews International, Baillie Gifford, Motilal Oswal, and First Ray Capital (Singapore) across late August to early September at its Gurugram office and virtually.

  • Prabhudas Lilladher meet in Noida Aug 25

    Global Health hosted an in-person session with analysts and institutional investors in Noida on Aug 31, organized by Prabhudas Lilladher Capital, featuring one-to-one and group discussions.

TL;DR: Global Health's news flow over the past month is dominated by a steady drumbeat of analyst and investor meetings with both domestic and global institutional players, reflecting sustained interest in the stock. The proposed ₹0.50 dividend and upcoming AGM on Sep 16 are routine but mildly positive governance signals. No material headwinds or negative developments surfaced during this period. The trend is stable with the high frequency of investor engagement suggesting the company is actively courting capital ahead of potential expansion or strategic updates.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
780
844
836
809
861
957
943
931
1,031
1,099
1,121
1,159
1,304
Expenses
595
631
620
629
675
728
706
707
784
868
904
915
1,017
Operating Profit
184
213
216
179
186
228
238
225
247
231
217
244
287
OPM %
24%
25%
26%
22%
22%
24%
25%
24%
24%
21%
19%
21%
22%
Other Income
15
21
18
27
22
18
16
-27
20
36
-15
37
22
Interest
18
20
18
18
18
16
16
15
14
17
22
27
27
Depreciation
40
43
44
45
47
49
48
49
45
50
61
67
69
PBT
141
171
172
143
144
181
189
133
208
200
120
187
213
Tax %
28%
27%
28%
11%
26%
28%
24%
24%
24%
21%
21%
24%
26%
Net Profit
102
125
124
127
106
131
143
101
159
158
95
142
157
EPS in Rs
3.8
4.66
4.61
4.74
3.96
4.87
5.32
3.78
5.92
5.89
3.54
5.36
5.9
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,382
1,343
1,456
1,500
1,447
2,167
2,710
3,275
3,692
4,410
4,683
Expenses
1,081
1,218
1,283
1,309
1,250
1,709
2,073
2,466
2,806
3,480
3,705
Operating Profit
301
125
172
192
197
458
637
809
886
930
979
OPM %
22%
9%
12%
13%
14%
21%
24%
25%
24%
21%
21%
Other Income
45
49
50
44
31
39
49
75
29
98
80
Interest
14
28
38
57
73
86
86
84
74
90
92
Depreciation
70
86
102
115
123
130
150
173
194
223
246
PBT
262
60
83
64
32
281
449
627
647
715
720
Tax %
35%
45%
38%
43%
11%
30%
27%
24%
26%
23%
—
Net Profit
170
33
51
36
29
196
326
478
481
554
552
EPS in Rs
35.1
6.78
10.44
7.36
5.81
7.75
12.16
17.81
17.92
20.7
20.69
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
2%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
48
48
49
49
50
51
54
54
54
54
Reserves
976
1,136
1,246
1,300
1,333
1,565
2,375
2,852
3,333
3,908
Borrowings
165
456
787
929
931
1,109
1,122
802
718
1,190
Other Liabilities
295
343
347
388
380
421
547
572
662
753
Total Liabilities
1,485
1,984
2,430
2,666
2,694
3,146
4,097
4,280
4,766
5,905
Fixed Assets
914
1,094
1,194
1,703
1,616
1,776
2,050
2,236
2,514
3,795
CWIP
12
317
666
382
464
439
327
388
533
132
Investments
0
0
0
0
0
0
0
0
3
3
Other Assets
559
573
570
581
615
930
1,720
1,656
1,716
1,975
Total Assets
1,485
1,984
2,430
2,666
2,694
3,146
4,097
4,280
4,766
5,905
Figures in ₹ Crores

Cash Flow

Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
228
63
166
175
242
311
645
612
624
714
Investing
-241
-69
-249
-87
-239
-421
-342
-441
-721
-1,089
Financing
-7
9
97
-1
-81
160
346
-514
-97
272
Net Cash Flow
-20
3
14
87
-78
50
648
-343
-194
-103
Free Cash Flow
71
-81
-133
-13
100
38
409
335
110
-123
CFO/OP
108
93
135
121
131
89
118
98
89
90
Figures in ₹ Crores

Ratios

Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
20
41
41
36
34
30
26
24
29
34
Inventory Days
28
26
26
43
42
36
35
32
28
29
Days Payable
92
124
142
147
138
90
114
90
81
89
Cash Conversion Cycle
-45
-56
-75
-67
-62
-24
-52
-34
-24
-26
Working Capital Days
-23
-33
-18
-31
-48
-20
-37
-32
-21
-7
ROCE %
—
—
6%
6%
5%
15%
17%
20%
20%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Global Health insights

61 extracted metrics + investor summaries across FY16–FY27.

Log in — free

Shareholding Pattern

Promot.33.00%Others35.05%Public5.60%FIIs9.46%DIIs16.89%As ofJun 2026

Documents

Frequently Asked Questions about Global Health

What does Global Health Ltd do?
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transp...
Where is Global Health Ltd (MEDANTA) listed?
Global Health Ltd trades as MEDANTA on the NSE and under code 543654 on the BSE.
Which sector does Global Health Ltd belong to?
Global Health Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the market capitalisation of Global Health Ltd?
Global Health Ltd has a market capitalisation of ₹38,784 Cr, which places it in the Large Cap band.
What is the PE ratio of Global Health Ltd?
Global Health Ltd trades at a PE ratio of 69.95, on earnings per share of ₹17.97, against a book value of ₹147.34 per share.
What is the 52-week high and low of Global Health Ltd?
Over the last 52 weeks Global Health Ltd has traded between ₹956 and ₹1,544.
Does Global Health Ltd pay dividends?
Global Health Ltd has a dividend yield of 0.03%.
What is the Return on Equity (ROE) of Global Health Ltd?
Global Health Ltd reported a return on equity of 13.91%. Its debt-to-equity ratio is 0.30.

Company Information

Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]

Website medanta.org
Listed 2022-11-16
Face Value ₹ 2
Issued Size 26,87,90,382

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDANTA.md for Global Health Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare Services → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List